Chandrashekhar Athare: EHA 2026 Concludes with Lasting Impact and New Collaborations
Chandrashekhar Athare, Associate Director at Innomagine Consulting Private Limited, shared a post on LinkedIn:
“As EHA 2026 comes to a close, I would like to express my gratitude to the organizers, speakers, exhibitors, and fellow attendees for an excellent congress in Stockholm.
Over the past few days, I had the opportunity to learn about the latest advancements in hematology, attend inspiring scientific sessions, and connect with professionals from across the global healthcare and life sciences community.
The insights gained, conversations shared, and connections made will undoubtedly contribute to future collaborations and continued learning.
A special thanks to everyone who took the time to connect and exchange ideas.
I look forward to staying in touch and continuing these discussions beyond the congress.
Until next time—looking forward to EHA 2027!”
Stay updated with Hemostasis Today.
-
Nov 15, 2026, 10:32Ibrahim Gwarzo: Identifying Care Gaps and Emergency Pain Delays in Sickle Cell Disease at APHA 2026
-
Nov 15, 2026, 10:17Ify Osunkwo: How the Sickle Cell Community Can Influence FDA Drug Development Priorities
-
Nov 15, 2026, 10:11Ahmed Abdelsalam: Why Matching ABO and RhD Groups Does Not Guarantee Crossmatch Compatibility
-
Nov 15, 2026, 10:06Asma Khalil: New British Society for Haematology Guidance on Paediatric and Neonatal Transfusion
-
Nov 15, 2026, 09:41Girishkumar Modi: Navigating the 2026 Jehovah’s Witness Transfusion Policy Shift in Clinical Practice
-
Nov 15, 2026, 04:31Aakriti Gupta: Anticoagulation for Leaflet Thickening After TAVR
-
Nov 14, 2026, 23:57Jamie S. Y. Ho: Exploring the Mechanisms of Arterial Thrombosis and the Evolution of Antithrombotic Therapy
-
Nov 14, 2026, 23:53Jacopo Imberti: The Past, Present and Future of Arterial Thrombosis Research
-
Nov 14, 2026, 23:48Shrouk Ramadan: Joining the Editorial Review Board of Clinical and Applied Thrombosis and Hemostasis